Sequential gemcitabine and docetaxel proves efficacious in NMIBC. (cover story)

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Abstract:
      The article reports on the findings of research which suggests that intravesical gemcitabine/docetaxel is necessary for patients with BCG failure and that it is effective in non-muscle-invasive bladder cancer (NMIBC). Common adverse effects were urgency and frequency and dysuria. Study participants included patients treated at nine centers for recurrent NMIBC.